Key result
New anatomical and functional imaging trials show potential to radically change SIHD management.
Ongoing and recently published clinical trials of imaging-based strategies have the potential to bring radical changes to the diagnosis and management of stable ischaemic heart disease.
No immediate practice change for stable IHD diagnosis; leaves open whether imaging strategies will redefine management.
Chest pain and coronary artery disease (CAD) impose a substantial burden on public health and society. Diagnostic imaging tests are used by clinicians to identify the presence and extent of epicardial coronary disease and/or its consequences, including ischaemia, infarction, and left ventricular dysfunction. In this article, we discuss current practice guideline recommendations for the diagnosis and management of patients with suspected or known CAD, and the need for more evidence from clinical trials. We then focus on the recently published and ongoing multicentre clinical trials of imaging-based strategies for the diagnosis and management of ischaemic heart disease, and the potential future impact of these trials on clinical practice. The results of these trials have the potential to bring radical changes to the practice of cardiology in the future.
No takes yet. Share an insight, caveat, or question.
Corcoran et al. (2016) conducted a review in Stable Ischaemic Heart Disease. Imaging-based diagnostic strategies (e.g., CTCA, CMR, PET) vs. Standard care or functional testing was evaluated. Ongoing and recently published clinical trials evaluating anatomical and functional imaging-based diagnostic strategies have the potential to radically change the management of stable ischaemic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: